1y return+92.1%S&P 500 +20.9%
3y return+266.3%S&P 500 +68.5%
5y return+42.6%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since March 31, 2021: $133 against $188 in the S&P 500.2
Aisling Capital Management LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| BBIOBridgebio Pharma Inc | $341.8M | 72.5% | −9.8% |
| GLUEMonte Rosa Therapeutics Inc | $37.6M | 8.0% | |
| SNDXSyndax Pharmaceuticals Inc | $28.8M | 6.1% | |
| CMPSCompass Pathways PLC | $20.3M | 4.3% | |
| BCAXBicara Therapeutics Inc | $16.9M | 3.6% | |
| BBOTBridgebio Oncology Therapeut | $7.8M | 1.6% | |
| SRRKScholar Rock Hldg Corp | $4.2M | 0.9% | |
| Urogen Pharma LtdCUSIP M96088105 | $4.0M | 0.8% | |
| BMEABiomea Fusion Inc | $3.0M | 0.6% | |
| ACRSAclaris Therapeutics Inc | $2.3M | 0.5% | |
| EPRXEupraxia Pharmaceuticals Inc | $2.1M | 0.5% | |
| VTVTVtv Therapeutics Inc | $1.9M | 0.4% | New |
| MRKRMarker Therapeutics Inc | $478K | 0.1% | |
| OKUROnkure Therapeutics Inc | $404K | 0.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| BBIOBridgebio Pharma Inc | June 30, 2020 | +128.4% | $341.8M |
| CMPSCompass Pathways PLC | September 30, 2023 | +91.2% | $20.3M |
| Urogen Pharma LtdCUSIP M96088105 | December 31, 2025 | +57.1% | $4.0M |
| SRRKScholar Rock Hldg Corp | September 30, 2025 | +47.7% | $4.2M |
| SNDXSyndax Pharmaceuticals Inc | June 30, 2020 | +47.5% | $28.8M |
| BCAXBicara Therapeutics Inc | September 30, 2024 | +16.6% | $16.9M |
| GLUEMonte Rosa Therapeutics Inc | June 30, 2021 | +6.6% | $37.6M |
| EPRXEupraxia Pharmaceuticals Inc | March 31, 2026 | −8.7% | $2.1M |
| BBOTBridgebio Oncology Therapeut | September 30, 2025 | −34.2% | $7.8M |
| OKUROnkure Therapeutics Inc | December 31, 2024 | −47.0% | $404K |
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +6.4% | +14.8% |
| March 31, 2026 | −1.7% | −4.6% |
| December 31, 2025 | +48.3% | +2.4% |
| September 30, 2025 | +23.9% | +7.8% |
| June 30, 2025 | +23.0% | +10.5% |
| March 31, 2025 | +17.6% | −4.6% |
| December 31, 2024 | +7.1% | +2.1% |
| September 30, 2024 | +9.6% | +5.4% |
| June 30, 2024 | −19.7% | +4.0% |
| March 31, 2024 | −15.8% | +10.0% |
| December 31, 2023 | +43.7% | +11.2% |
| September 30, 2023 | +15.6% | −3.6% |
| June 30, 2023 | −2.1% | +8.3% |
| March 31, 2023 | +30.1% | +7.0% |
| December 31, 2022 | +2.8% | +7.1% |
| September 30, 2022 | +8.4% | −5.3% |
| June 30, 2022 | −13.4% | −16.5% |
| March 31, 2022 | −33.9% | −4.9% |
| December 31, 2021 | −41.5% | +10.7% |
| September 30, 2021 | −18.2% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Aisling Capital Management LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1766721&type=13F-HR&dateb=&owner=include&count=40CIK 1766721
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1766721/000176672126000003/Filed August 13, 2026 · accession 0001766721-26-000003